The oocyte and its role in regulating ovulation rate: a new paradigm in reproductive biology

K P McNatty, L G Moore, N L Hudson, L D Quirke, S B Lawrence, K Reader, J P Hanrahan, P Smith, N P Groome, M Laitinen, O Ritvos and J L Juengel

AgResearch, Wallaceville Animal Research Centre, PO Box 40063, Upper Hutt, New Zealand, Teagasc, Athenry Research Centre, Athenry, Ireland, School of BMS, Oxford Brookes University, Gipsy Lane, Headington, Oxford OX3 OBP, UK and Biomedicum Helsinki, PO Box 63 (Haartmaninkatu 8), FIN-00014, University of Helsinki, Helsinki, Finland

Correspondence should be addressed to Ken P McNatty; Email: ken.mcnatty@agresearch.co.nz

Abstract

Ovulation rate in mammals is determined by a complex exchange of hormonal signals between the pituitary gland and the ovary, and by a localised exchange of hormones within ovarian follicles between the oocyte and its adjacent somatic cells (Dong et al. 1996, Galloway et al. 2000, Eppig 2001, Richards 2001, Findlay 2003). From examination of inherited patterns of ovulation rate in sheep, point mutations have been identified in two oocyte-expressed genes, BMP15 (GDF9B) and GDF9. Animals heterozygous for any of these mutations have higher ovulation rates (that is, + 0.8–3) than wild-type contemporaries, whereas those homozygous for each of these mutations are sterile with ovarian follicular development disrupted during the preantral growth stages. Both GDF9 and BMP15 proteins are present in follicular fluid, indicating that they are secreted products. In vitro studies show that granulosa and/or cumulus cells are an important target for both growth factors. Multiple immunisations of sheep with BMP15 or GDF9 peptide protein conjugates show that both growth factors are essential for normal follicular growth and the maturation of preovulatory follicles. Short-term (that is, primary and booster) immunisation with a GDF9 or BMP15 peptide-protein conjugate has been shown to enhance ovulation rate and lamb production. In summary, recent studies of genetic mutations in sheep highlight the importance of oocyte-secreted factors in regulating ovulation rate, and these discoveries may help to explain why some mammals have a predisposition to produce two or more offspring rather than one.

Introduction

Ovulation rate in mammals is determined by a complex exchange of hormone signals between the pituitary gland and the ovary, and by a localised exchange of hormones within ovarian follicles between the oocyte and its adjacent somatic cells (Dong et al. 1996, Galloway et al. 2000, Eppig 2001, Richards 2001, Findlay 2003). From examination of inherited patterns of ovulation rate in sheep, several breeds have been identified with mutations in two growth factor genes that are expressed in oocytes, namely, bone morphogenetic protein 15 (BMP15), also known as growth differentiation factor 9B (GDF9B), and GDF9 (see McNatty et al. 2003 for review). BMP15 and GDF9 are two closely related members of the transforming growth factor-β (TGFβ) superfamily, many of which are important for regulating ovarian follicular development (Chang et al. 2002, Knight & Glister 2003, Lin et al. 2003, Shimasaki et al. 2004). However, what distinguishes BMP15 and GDF9 from other TGFβ superfamily members is that changing concentrations of these two factors in vivo leads to incremental changes in ovulation rate in sheep (Galloway et al. 2000, Juengel et al. 2002, 2003, McNatty et al. 2003, Hanrahan et al. 2004). The significance of these discoveries is that the oocyte appears to regulate the growth and differentiation of adjacent somatic cells as well as their responsiveness to endocrine signals and thereby the number of follicles that mature and ovulate.

The purpose of this review is to summarise recent results showing that BMP15 and GDF9 are important factors regulating ovulation rate. Particular emphasis will be placed on the BMP15 and GDF9 mutations and physiological results arising from studies in sheep.

Some functional and structural properties of BMP15 and GDF9

Within the ovary, both BMP15 and GDF9 mRNA and protein are localised exclusively to the oocyte. The only
exception to this is that GDF9 mRNA and protein have been localised to granulosa cells immediately adjacent to the oocyte in some primates (Sidis et al. 1998, Duffy 2003). It is also worth noting that BMP15 and GDF9 mRNA have been identified in the pituitary glands and testes of some species, albeit in limited amounts (Fitzpatrick et al. 1998, Otsuka & Shimasaki 2002), suggesting that these factors have some regulatory roles in other tissues.

In sheep, BMP15 mRNA and protein are not present until follicles have just begun to grow (that is, the primary stage of development): thereafter, BMP15 is localised to oocytes of most, if not all, developing follicles (Galloway et al. 2000, Juengel et al. 2002). GDF9 mRNA and protein can be identified in sheep oocytes during follicular formation, in primordial (type 1) follicles and in oocytes at all stages of follicular growth (Bodensteiner et al. 1999, Juengel et al. 2002, Mandon-Pepin et al. 2003). Under in vitro conditions, GDF9 protein is present in both normal-looking and degenerating ovine oocytes, and even in highly disorganised follicular structures, indicating that its distribution is widespread in oocytes notwithstanding the functional status of its surrounding somatic cells (unpublished data). There are species differences with respect to the ontogeny of expression of both BMP15 and GDF9 during follicular development (Aaltonen et al. 1999, Eckery et al. 2002, Erickson & Shimasaki 2003).

Like other TGF-β superfamily members, BMP15 and GDF9 are translated as preproproteins composed of a signal peptide, a large proregion and a smaller mature region (Fig. 1). After removal of the signal peptide, further intracellular processing results in the separation of the biologically active mature region from the proregion (Kingsley et al. 2004). The nature of the interactions between these factors have some regulatory roles in other tissues.

Under reducing conditions, both the mature and unprocessed promature forms of BMP15 and GDF9 can be identified in follicular fluid from sheep (unpublished data). The nature of the interactions between homodimers of BMP15 or GDF9 or putative BMP15/GDF9 heterodimers and type I and II receptors is still unresolved, but the downstream signalling pathway involves activation of the Smad proteins (Heldin et al. 1997, Miyazono 2000, Kloos et al. 2002). The effects of BMP15 or GDF9 on follicular cell DNA or steroid synthesis remain to be resolved but appear to differ across species (see Shimasaki et al. 2004 for a recent review).

Figure 1 Schematic outline of the BMP15 and GDF9 molecules.

Figure 2 Molecular surface representation of a putative heterodimer (BMP15/GDF9) bound to the extracellular domains of two type II receptors (ALK5) and two type II receptors (BMPRII). Arrows indicate the BMP15 (green) and GDF9 (red) molecules, whereas ALK5 and ALK6 are coloured light and dark blue respectively and BMPRII coloured yellow. The non-covalently linked GDF9 and BMP15 molecules can be compared with the palms of each hand in contact with one another, and the BMPRII receptors attached to the knuckles and the ALK5 and ALK6 receptors to the fingertips.
BMP15 and GDF9 mutations in sheep and their effects on ovulation rate

Sheep BMP15 maps to the X chromosome, and the full-length coding sequence of 1179 nucleotides encodes a preproprotein region of 268 amino-acid residues and a mature protein region of 125 amino-acid residues (Galloway et al. 2000). Sheep GDF9 maps to chromosome 5 (Sadiqhi et al. 2002), and the full-length coding sequence of 1359 nucleotides encodes a preproprotein region of 318 amino-acid residues and a mature protein region of 135 amino-acid residues (Fig. 1) (Bodensteiner et al. 1999).

Currently, five different point mutations have been identified in the BMP15 gene and one in the GDF9 gene, each having a major effect on ovulation rate (Galloway et al. 2000, Bodin et al. 2003, Hanrahan et al. 2004). These point mutations in BMP15 and GDF9 and the resulting amino-acid changes are summarised in Table 1. All animals heterozygous for any one of these BMP15 or GDF9 mutations have increased ovulation rates, whereas homozygous individuals are sterile with normal ovarian follicular development arrested or abnormal from the type 2 stage of growth (Braw-Tal et al. 1993, Galloway et al. 2000, Bodin et al. 2003, Hanrahan et al. 2004, unpublished data). From in vitro studies, using a cell line expressing recombinant human BMP15 with the FecX1 or FecX8 sheep mutation or recombinant human GDF9 with the sheep FecXH mutation (Table 1), it was found that the secretion levels of both proteins were significantly lower than those in the wild-types (Liao et al. 2004). Surprisingly, equivalent concentrations of the homozgyous mutant forms of BMP15 or GDF9 protein had similar levels of biological activity to that of the wild-type proteins when assessed by a thymidine incorporation assay using rat granulosa cells. The implication of these findings is that sheep with the homozgyous mutations FecX8, FecXH or FecX1 would have biologically active BMP15 or GDF9, although not in sufficient amounts to support ovarian follicular growth since the ovarian phenotypes in these animals are similar to those in animals having the FecX18 or FecX8 stop codons and thus, presumably, no biologically active protein.

The mean ovulation rates of F700 Belclare, Cambridge, Hanna and Inverdale ewes heterozygous for the known BMP15 and GDF9 mutations, together with the effects of the mutations on the BMP15 or GDF9 protein or their possible interactions with a type I or II binding domain, are summarised in Table 2. Animals with a likely 50% reduction in intrafollicular concentrations of BMP15 (FecXG, FecXH or FecX1) have a mean ovulation rate increase of 35–67%, whereas animals heterozygous for a mutation in the region of BMP15 or GDF9 that interacts with a type I or II receptor (FecX10 or FecX11) have mean ovulation rate increases of 87–95%. Of interest are the animals that are heterozygous for mutations in both BMP15 and GDF9 (such as FecXG and FecXH, and FecX8 and FecX1) . These animals are likely to have reduced concentrations of BMP15 and possibly an altered interaction between GDF9 and its type I receptor (such as FecX10 and FecX11) or an altered interaction for both BMP15 and GDF9 with their receptor-binding domains (FecX8 and FecX1). The consequence of these double mutations appears to be a synergistic effect on ovulation rate (Table 2). The mean ovulation rates in Lacaune ewes, heterozygous for the BMP15 mutation leading to a tyrosine substituting for a cysteine at mature peptide residue 53 (FecX1; Table 1), is not known, as carrier animals currently identified have another co-dominant mutation on chromosome 11 (Bodin et al. 2003).

The evidence from gene-knockout studies in mice suggests that BMP15 and GDF9 may not affect follicular development and ovulation rate in a similar manner in all species. Female mice lacking a functional GDF9 gene are infertile and have an ovarian phenotype similar to that described for sheep homozygous for the BMP15 (FecXG, FecX8, FecXH, FecX1 and FecX8) or the GDF9 mutations (FecX1) (Table 1) (Braw-Tal et al. 1993, Dong et al. 1996, Galloway et al. 2000, unpublished data). However, mice lacking a functional BMP15 gene have apparently normal follicular development and are fertile, although litter size is reduced by impaired fertilisation of oocytes (Yan et al. 2001). Mice heterozygous for an inactive copy of the BMP15 or GDF9 gene appear to have normal litter sizes, whereas those heterozygous for inactive copies of both a BMP15 and a GDF9 gene have reduced litter sizes: this effect was enhanced in mice without a functional BMP15 gene and heterozygous for an inactive GDF9 gene. In all cases, it seems that follicular growth was normal but that fertilisation of the oocyte was seriously impaired. The reason for the reduced litter size was thought to be inappropriate development of the oocyte–cumulus cell complex, as many oocytes were recovered with few, if any, attached cumulus cells (Yan et al. 2001).

Table 1 Polymorphic sequence variations in BMP15 and GDF9 that affect ovarian follicular development and ovulation rate in sheep.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Allele</th>
<th>Base change</th>
<th>Coding residue (aa)</th>
<th>Mature peptide residue (aa)</th>
<th>Amino-acid change</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMP15</td>
<td>FecXG</td>
<td>C → T</td>
<td>239</td>
<td>Glu → STOP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FecX8</td>
<td>G → T</td>
<td>367</td>
<td>Ser → Ile</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FecX1</td>
<td>T → A</td>
<td>299</td>
<td>Val → Asp</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FecXH</td>
<td>C → T</td>
<td>291</td>
<td>Glu → STOP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FecX10</td>
<td>G → A</td>
<td>321</td>
<td>Cys → Tyr</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FecX11</td>
<td>C → T</td>
<td>395</td>
<td>Ser → Phe</td>
<td></td>
</tr>
<tr>
<td>GDF9</td>
<td>FecXG</td>
<td>C → T</td>
<td>395</td>
<td>Glu → STOP</td>
<td></td>
</tr>
</tbody>
</table>

Data from Galloway et al. (2000), Bodin et al. (2003) and Hanrahan et al. (2003). For the purposes of this report, the BMP 15 mutation in Lacaune sheep was assigned the allele FecX1. This mutation was found as a co-dominant mutation in a Lacaune breed with an autosomal gene. aa = amino acid.

www.reproduction-online.org
Regulation of ovulation rate by altering BMP15 and GDF9 concentrations in vivo

The implication of the ovulation rate outcomes in sheep heterozygous for mutations in either BMP15 or GDF9 is that the absence or extremely low concentrations of either of these factors leads to an inhibition of ovarian follicular development and thus sterility, whereas a partial reduction in concentrations of these factors increases ovulation rate and thus litter size (Davis et al. 2001, Hanrahan et al. 2004). Inverdale ewes heterozygous for the BMP15 mutation (FecXI) have similar concentrations of plasma follicle-stimulating hormone (FSH) and luteinizing hormone (LH) to their wild-type contemporaries. Moreover, the ovarian secretions of steroids are not different between the heterozygous and wild-type Inverdales, notwithstanding the fact that in heterozygotes the mean ovulation rate is higher and there are more oestrogenic follicles (Shackell et al. 1993). The underlying cause of the higher ovulation rate in heterozygous Inverdales appears to be the precocious maturation of small follicles due to increased FSH responsiveness and an earlier acquisition of LH receptors by the granulosa cells (Shackell et al. 1993). The underlying cause of the higher ovulation rate in heterozygous Inverdales appears to be the precocious maturation of small follicles due to increased FSH responsiveness and an earlier acquisition of LH receptors by the granulosa cells (Shackell et al. 1993). This is consistent with the in vitro studies of Otsuka et al. (2001) showing that BMP15 can cause suppression of FSH receptor expression in rat granulosa cells, thereby suggesting that reduced BMP15 concentrations are associated with a higher level of FSH responsiveness. Moreover, the higher ovulation rate in ewes heterozygous for the GDF9 mutation FecG15 is consistent with at least one report showing that GDF9 inhibits FSH actions in rat granulosa cells in vitro by inhibiting FSH-dependent LH receptor expression, CAMP production, oestradiol and progesterone synthesis (Vitt et al. 2000).

Since the oocyte is a major source of both BMP15 and GDF9 and the major target for these factors is the granulosa cells (see Shimasaki et al. 2004 for a review), it is reasonable to infer that these oocyte-derived growth factors modulate the responsiveness of granulosa cells to the gonadotrophins. We therefore asked whether the intrafollicular concentrations of BMP15 or GDF9 could be modulated by exogenous means to alter ovulation rate. We have addressed this question, using sheep as our experimental model, and the results from such studies have been very informative.

Long-term immunisations with BMP15 or GDF9 peptides

In one study, ewes were immunised with either keyhole limpet haemocyanin (KLH) or KLH conjugated to either a 15 mer BMP15 or a GDF9 peptide sequence from the N-terminal end of each mature protein region (that is, BMP15 peptide 1 or GDF9 peptide 1) (see Juengel et al. 2002). The immunisations, which took place before and during the breeding season, were given i.m. a month apart in Freund’s adjuvant for 7 months. Ewes immunised with KLH alone (9/9) maintained regular oestrous cycles of 17 ± 2 days during the breeding season. By contrast, most ewes immunised against BMP15 (9/10) or GDF9 (10/10)

<table>
<thead>
<tr>
<th>Wild-type, mutation or immunisation</th>
<th>Predicted effect on BMP15, GDF9 or receptor type</th>
<th>Hannaa</th>
<th>Inverdalea</th>
<th>F700 Belclareb</th>
<th>Cambridgeb</th>
<th>Romneyc (immunised)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT None</td>
<td>Reduced concentrations of mature BMP15</td>
<td>1.8</td>
<td>1.8</td>
<td>1.9</td>
<td>2.3</td>
<td>1.6</td>
</tr>
<tr>
<td>FecX1 (BMP15)</td>
<td>Reduced concentrations of mature BMP15</td>
<td>3.0 (+67%)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>FecX2 (BMP15)</td>
<td>Reduced concentrations of mature BMP15</td>
<td>–</td>
<td>2.9 (+61%)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>FecX3 (BMP15)</td>
<td>Disrupted interaction type II with the receptor-binding domain</td>
<td>–</td>
<td>–</td>
<td>2.7 (+42%)</td>
<td>3.1 (+35%)</td>
<td>–</td>
</tr>
<tr>
<td>FecX4 (BMP15)</td>
<td>Disrupted interaction with the type I receptor-binding domain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4.3 (+87%)</td>
<td>–</td>
</tr>
<tr>
<td>FecX5 &amp; FecX6 (BMP15)</td>
<td>Reduced concentrations of mature BMP15 and disrupted interactions with a type I receptor-binding domain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>5.8 (+152%)</td>
<td>–</td>
</tr>
<tr>
<td>FecX7 (GDF9)</td>
<td>Disrupted interaction with the type I receptor-binding domain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>6.1 (+221%)</td>
<td>–</td>
</tr>
<tr>
<td>FecX8 &amp; FecX9 (GDF9)</td>
<td>Disrupted interaction with a putative type I receptor-binding domain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2.9 (+81%)</td>
<td></td>
</tr>
<tr>
<td>Immunised (BMP15–peptide 2)</td>
<td>Disrupted interaction with a putative type I receptor-binding domain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>3.5 (+121%)</td>
</tr>
<tr>
<td>Immunised (GDF9 peptide 2)</td>
<td>Disrupted interaction with a putative type I receptor-binding domain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

WT = wild-type animals.

a Davis et al. 2001.
c Unpublished data.
failed to show normal oestrous behaviour throughout the breeding season. Similarly, most of the BMP15- and GDF9-immunised ewes showed no evidence of ovulation or normal patterns of luteal progesterone concentrations. When the ovaries were examined at the end of the experiment (7.5 months after the initial immunisation), it was evident that normal follicular development beyond the type 2 stage of growth did not occur in either the BMP15- or GDF9-immunised animals and that the phenotype was similar to that observed in ewes homozygous for mutations in BMP15 or GDF9 (Braw-Tal et al. 1993, Galloway et al. 2000, Hanrahan et al. 2004, unpublished data). As shown by ELISA, ewes immunised against the BMP15 peptide had high antibody titres against ovine (o) BMP15 but showed no cross-reactivity (that is, <1%) to oGDF9. Likewise, ewes immunised with the GDF9 peptide contained antibodies against oGDF9 protein, but not against oBMP15 protein. These data show that secreted forms of both BMP15 and GDF9 are essential for follicular development and ovulation rate in sheep. The aforementioned BMP15 and GDF9 amino-acid sequences (that is, peptide 1) correspond to flexible regions of the respective mature protein regions, and it is not known whether these regions are close to a binding site or a region important for dimerisation. To evaluate the affect of immunising sheep against alternative peptide sequences, we conjugated a 16 mer BMP15 peptide sequence (BMP15, peptide 2) or a 15 mer GDF9 peptide sequence (GDF9, peptide 2), near a putative type 1 receptor-binding region to KLH. Ewes (n = 9–10 per group), including a KLH control group, were immunised at monthly intervals in Freund’s adjuvant, starting in the non-breeding season and continuing through the breeding season (six monthly injections). The ewes in all treatment groups underwent normal cyclical oestrous activity, and there was no evidence either at laparoscopy (on two separate occasions) or at ovary recovery that any of these treatments caused a reduction in ovarian follicular development. Indeed, the mean ± S.E.M. ovulation rates were, on most occasions, significantly higher in both the BMP15- and GDF9-treated groups than in the KLH control group (Table 3). When the antibody responses were tested by ELISA, all the BMP15 and GDF9 animals produced antibody responses to BMP15 and GDF9 respectively, but none of the KLH control immunised animals produced antibodies to either BMP15 or GDF9. The overall mean ovulation rate increases following the BMP15 (peptide 2) or GDF9 (peptide 2) immunisations were similar to those observed for the heterozygous sheep (FecXB and FecGH), where there were mutations in the regions of BMP15 or GDF9 that interact with the type I or II receptors (see Table 2).

### Short-term treatments with BMP15 or GDF9 antibodies

Short-term passive immunisation studies using ovine antiplasma against BMP15 (peptide 1) or GDF9 (peptide 1) indicated that both BMP15 and GDF9 are important for the final phases of follicular maturation (Juengel et al. 2002). This conclusion was based on the following experimental results: four of the five ewes receiving antiplasma against BMP15 failed to ovulate, and three of the five ewes were devoid of surface visible follicles. All ewes (n = 5) receiving antiplasma against the GDF9 peptide formed one or two corpora lutea, but three of five ewes displayed abnormal luteal phase patterns of progesterone concentrations. All ewes (n = 4) receiving KLH antiplasma ovulated with normal luteal phase patterns of progesterone concentration.

### Short-term immunisations with BMP15 or GDF9 peptides

A number of BMP15 and GDF9 peptide formulations have been tested for their ability to increase ovulation, fertilisation or lambing rates (Juengel et al. 2003, McNatty et al. 2003, unpublished data). The concept being tested is whether it is possible to mimic reliably the lambing and/or ovulation rate increases that are found in ewes that have heterozygous mutations in either BMP15 or GDF9 (Davis et al. 2001, Hanrahan et al. 2003) (Table 1). Using a primary and single booster vaccination with BMP15 (peptide 1) or GDF9 (peptide 1) conjugated to bovine serum albumin (BSA) in a water-based adjuvant, Juengel et al. (2003) reported consistent and significant increases in ovulation rate in ewes immunised with GDF9 peptide (+22%; P < 0.05 (x2 analysis); n = 30 animals) or BMP15 peptide (+44%; P < 0.05 (x2 analysis); n = 30 animals) compared with BSA-immunised controls (n = 50 animals). Importantly, no adverse effects were observed on fertilisation, embryo survival or ability of ewes to maintain their pregnancy.

A larger study, using BMP15 peptide 1 conjugated to a carrier protein (n = 94 animals) or carrier protein alone (n = 49 animals) with the same water-based adjuvant as described above (see Juengel et al. 2003), recorded a 25% increase in both ovulation and lambing rate in the BMP15-immunised group relative to the carrier protein control group (both P < 0.05 (student’s t-test); unpublished data).

---

**Table 3** Mean ovulation rates in ewes following long-term immunisation with KLH, KLH-GDF9 peptide 2, or KLH-BMP15 peptide 2.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mean ovulation rate (± S.E.M.)</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLH</td>
<td>1.6 ± 0.2a</td>
<td>10</td>
</tr>
<tr>
<td>KLH-GDF9 (2)</td>
<td>3.6 ± 0.5b</td>
<td>10</td>
</tr>
<tr>
<td>KLH-BMP15 (2)</td>
<td>3.1 ± 0.4b</td>
<td>9</td>
</tr>
</tbody>
</table>

N = number of ewes. Values with different superscripts are significantly different, P < 0.01. Unpublished data.

GDF9 peptide 2 and BMP 15 peptide 2 refer to 15 or 16 mer peptides near a putative BMP type 1 receptor-binding region.
Possible molecular forms of BMP15 and GDF9 in regulating ovulation rate in sheep

GDF9 and BMP15 potentially could function as homodimers, heterodimers, a combination of the two or some other configuration. We have examined a number of possible relationships between ovulation rate and GDF9 and BMP15 acting as either homodimers or heterodimers. The ovulation rate data considered are those shown in Table 1 for sheep heterozygous for the FecXH, FecXG, FecXB, FecG1H, FecC1G, or FecG1H mutations. The assumptions that were made for GDF9 and BMP15 functioning as homodimers were as follows: (1) that the BMP mutations generating stop codons (FecXH and FecXG) (Tables 1 and 2) or the Inverdale (FecXI) variant of BMP15 (Tables 1 and 2) reduces biological activity at the level of the receptor(s) to 0.5 times that of the wild-type; (2) the mutations in the regions of BMP15 or GDF9 that interact with the type I or II receptors (FecXH, FecXG, and FecG1H) (Tables 1 and 2) reduce biological activity at the level of the receptor to 0.25 times that of the wild-type; and (3) mutations in both BMP15 and GDF9 are multiplicative, reducing biological activity at the level of the receptor(s) to 0.125 (FecXG and FecG1H; 0.5 × 0.25) and 0.0625 (FecXB and FecG1H; 0.25 × 0.25) times that of the wild-types. The assumptions made for FecXH or FecXG having only 50% of normal biological activity was based on the knowledge that these heterozygous animals would have only 50% of normal concentrations of mature BMP15 because only half of the normal amount of protein could be produced. Animals with the FecXI mutation were also given the figure of 50% of normal BMP15 activity on the assumption that the FecXI-produced BMP15 would not dimerise avidly with normal BMP15 protein (Galloway et al. 2000). For the FecXB or FecG1H mutations which require unmutated dimers for normal receptor function, the assumptions were based on the allelic frequency of normal biological activity being 25% of the wild-type because only 25% of homodimers in heterozygous animals consist of unmutated proteins. The multiplicative activities were derived from multiplying FecXG and FecG1H (that is, 0.5 × 0.25) or FecXB and FecG1H (that is, 0.25 × 0.25). Consequently, if BMP15 and GDF9 function as homodimers, the relationship between ovulation rate (y) and theoretical activation level of the receptor (x) as a fraction of the wild-type can be expressed by the equation $y = 146 \ln (x) + 68$ ($R^2 = 0.82; \ p < 0.001$; regression analysis).

From these assumptions, the preferred interpretation is that GDF9 and BMP15 affect follicular development and ovulation rate in sheep as functional homodimers. Verification of this hypothesis will require further in vivo and in vitro testing. It is important to note that the homodimer hypothesis does not exclude the notion of interactions between GDF9 and BMP15 either at the level of receptor or during the post-receptor signalling pathway. Moreover, it does not exclude the possibility that two heterodimers are necessary to activate a type I and II receptor complex.

Conclusion

Recent studies of genetic mutations in sheep highlight the importance of oocyte-secreted factors in regulating ovarian follicular development and ovulation rate. These findings, together with the immunisation results with BMP15 and GDF9 peptides, demonstrate that by altering the bioavailability of GDF9 and BMP15 in vivo, it is possible by exogenous means to enhance ovulation rate and increase lamb production or to induce infertility. Future studies with GDF9 and/or BMP15 peptides are aimed at translating these findings in sheep to regulating ovulation rate and numbers of offspring in other farmed animals, primates, wildlife or endangered species. The role of oocyte-derived growth factors in either up- or downregulating fertility is an exciting new paradigm in reproduction biology.

Acknowledgements

This paper was supported by the New Zealand Foundation for Research, Science and Technology; the Royal Society of New Zealand Marsden Fund; and Ovita Limited, Dunedin, New Zealand.

References


Bodensteiner KJ, Clay CM, Moeller CL & Sawyer HR 1999 Molecular cloning of the ovine growth/differentiation factor-9 gene and


Davis GH, Bruce GD & Dodds KG 2001 Ovulation rate and litter size of prolific Inverdale (FecX) and Hanna (FecX1) sheep. Proceedings of the Association for the Advancement of Animal Breeding and Genetics 14 175–178.


Eckery DC, Whale LJ, Lawrence SB, Wylde KA, McNatty KP & Juengel JL 2002 Expression of mRNA encoding growth differentiation factor 9 and bone morphogenetic protein 15 during follicular formation and growth in a marsupial, the brushtail possum (Trichosurus vulpecula). Molecular and Cellular Endocrinology 192 115–126.

Eppig JJ 2001 Oocyte control of ovarian follicular development and function in mammals. Reproduction 122 829–838.

Erickson GF & Shimasaki S 2003 The spatiotemporal expression pattern of the bone morphogenetic protein family in rat ovary cell types during the oestrous cycle. Reproductive Biology and Endocrinology 1 1–21.


Wilson T, Wu XY, Juengel JL, Ross IK, Lumsden JM, Lord EA, Dodds KG, Walling GA, McEwan JC, O’Connell AR, McNatty KP & Montgomery GW 2001 Highly prolific Booroola sheep have a mutation in the intracellular kinase domain of bone morphogenetic protein IB receptor (ALK-6) that is expressed in both oocytes and granulosa cells. *Biology of Reproduction* 64 1225–1235.